A survey of the medical literature for the past five years reveals that the use of typhoid shock therapy is less popular than during the preceding decade. This is probably due to lessened need for non-specific protein in treatment of infections and inflammatory processes. This is indicative of medical progress and reflects better understanding of the cause and treatment of disease. Yet in spite of the amazing bactericidal and bacteriostatic effects of the sulfa drugs and penicillin, we are confronted still with many medical conditions which are refractory to ordinary therapy. It is among these that nonspecific protein shock therapy has a useful place in clinical medicine.
In some instances typhoid vaccine given subcutaneously or intravenously merely relieves painful symptons, but in many cases it shortens the course of disease and contributes to recovery. Experience with its use in several thousand patients during a fifteen-year period has determined the course of administration and indications and contraindications for its use.
We know relatively little about chemical and biological changes that take place in the body during this type of shock therapy. However, it can be rightfully assumed that fever produced by proteins injected intravenously or subcutaneously causes active participation of cells of the body in production of a rise in body temperature. Furthermore, experience leads me to believe that defenses of the body against infection are mobilized not only by increased cellular oxidation but also by modification of cellular permeability, increased chemical exchange between the cells and body fluids, and favorable. . .